Additionally, the identification of the FOXP3-miR-146-NF-κB axis provides a mechanism for NF-κB activation as well as miR-146a/b disruption in breast and prostate cancer cells, allowing for a new therapeutic target in FOXP3 defect-related cancers. Here, NFKB1 is linked to Familial prostate cancer.